The red-pigmented astaxanthin (3,-3’-dihydroxy-?,?-carotene-4,4’-dione) were commonly found in marine algae and aquatic animals such as shrimp, lobster, and trout. These pigments are produced as secondary metabolites which fall in arytenoids under class xanthophylls. Synthetic astaxanthin has a wide range of commercial applications such as color additives, usage in cosmetics and immune-boosters. In aquaculture, supplementing synthetic astaxanthin as feed, enhances skin pigmentation which possesses commercial importance. However, synthetic astaxanthin is not highly efficient compared to naturally derived counter forms. On the other hand, humans should only depend on microbial and aquatic sources for their dietary intake of natural astaxanthin. Being a powerful antioxidant, natural astaxanthin is called as king of antioxidants which has scavenging activity 6000 times stronger than vitamin C and 50 times more powerful than vitamin E in protecting cell membranes. It also has a single oxygen quenching activity up to 800 times stronger than coenzyme Q, 550 times more powerful than green tea catechins, 4.9 times stronger than beta-carotene and three times stronger than lute in. Furthermore, researchers revealed that this carotenoid has the capacity to alleviate tumor activity, protecting against lipid per oxidation, free radicals, oxidative damage to LDL-cholesterol and UV light affects on cell membranes and tissues. Also, it is mainly recommended for curing the macular degeneration of cataracts. Anti-aging properties of astaxanthin improve skin health by reducing wrinkles and repairs the UV-induced DNA damage in human cells. Interestingly, the ability of astaxanthin in crossing the blood-brain barrier has brought this compound to limelight as a potential target in treating neurodegenerative diseases including Parkinson's and Alzheimer's disease. Hence, in this review, we are mainly focusing on the therapeutic usage of astaxanthin in neurodegenerative diseases.


Astaxanthin, carotenoid, neurodegenerative, anti-aging,


Download data is not yet available.


  1. Al-Amin, M.M.; Akhter, S.; Hasan, A.T.; Alam, T.; Hasan, S.N.; Saifullah, A.; Shohel, M. The antioxidant effect of astaxanthin is higher in young mice than aged: A region specific study on brain. Metab. Brain. Dis., 30, 1237–1246,2015..
  2. Chang, C.H.; Chen, C.Y.; Chiou, J.Y.; Peng, R.Y.; Peng, C.H. Astaxanthin secured apoptotic death of PC12 cells induced by ?-amyloid peptide Its molecular action targets,J. Med. Food, 13, 548–556,2010.
  3. Christian Galasso , Ida Orefice , Paola Pellone , Paola Cirino, Roberta Miele,Adrianna Ianora , Christophe Brunet and Clementina Sansone, “On the Neuroprotective Role of Astaxanthin: New Perspectives?, Marine drugs, July 2018.
  4. Damiano, S.; Sasso, A.; Accetta, R.; Monda, M.; De Luca, B.; Pavone, L.M.; Belfiore, A.; Santillo, M. Mondola, P. Effect of mutated Cu, Zn superoxide dismutase (SOD1G93A) on modulation of transductional pathway mediated by M1 muscarinic receptor in SK-N-BE and NSC-34 cells. Front. Physiol, 9, 611, 2018.
  5. Davielli., Sergio Davinelli, Michael E. Nielsen Giovanni Scapagnini ,Astaxanthin in Skin Health, Repair, and Disease: A Comprehensive Review,nutrients,10,52,2018.
  6. Dowell, F.; Martin, W.; Dominiczak, A.; Hamilton, C. Eur. J.Pharmacol., 379, 175-182,1999.
  7. EFSA, NDA Panel. Scientific opinion on the safety of astaxanthin-rich ingredients (AstaREAL A1010 and AstaREAL L10) as novel food ingredients EFSA panel on dietetic products, nutrition and allergies (NDA). EFSA J., 12, 1–35, 2014.
  8. Facchinetti F et al: Free radicals as mediators of neuronal injury. Cell. Mol. Neurobiol. 18: 667–682,1998.
  9. Galasso, C.; Corinaldesi, C.; Sansone, C. Carotenoids from marine organisms: Biological functions and industrial applications. Antioxidants , 6, 96,2017.
  10. Ghazi Hussein, Ushio Sankawa, Hirozo Goto, Kinzo Matsumoto and Hiroshi Watanabe,”Astaxanthin, a Carotenoid with Potential in Human Health and Nutrition”, American Chemical Society and American Society of Pharmacognosy, Journal of natural products, 2005.
  11. Grimming, B. Daly. L. Subbarayan, M. Hudson, C. Williamson, R. Nash, K. Bickford, P.C. Astaxanthin attenuates neurotoxicity in a mouse model of Parkinson’s disease. Oncotarget ,10388–10401,2018.
  12. Hussein G, Goto, H, Oda, S, Sankawa, U et al.,:Antihypertensive potential and mechanism of action of astaxanthin: III. Antioxidant and histopathological effects in spontaneously hypertensive rats. Biol Pharm Bull; 29:684–688, 2006.
  13. Ikeda, Y.; Tsuji, S.; Satoh, A.; Ishikura, M.; Shirasawa, T.; Shimizu, T. Protective effects of astaxanthin on 6-hydroxydopamine-induced apoptosis in human neuroblastoma SH-SY5Y cells. J. Neurochem., 107,1730–1740,2008.
  14. Irvine, G.B. El-Agnaf, O.M. Shankar, G.M.Walsh, D.M. Protein aggregation in the brain: The molecular basis for Alzheimer’s and Parkinson’s diseases. Mol. Med., 14, 451–464,2008.
  15. Isonaka, R.; Hiruma, H.; Katakura, T.; Kawakami, T. Inhibition of superoxide dismutase selectively suppresses growth of rat spinal motor neurons: comparison with phosphorylated neurofilament-containingspinal neurons. Brain Res., 1425, 13–19, 2011.
  16. Jyotika Dhankhar, Sumita S. Kadian and Asha Sharma,Astaxanthin: a potential carotenoid, IJPSR, Vol. 3(5): 1246-1259; 2012.
  17. Kang C. D,Han, S. J.,Choi,S.P.,and Sim,S.J Fed-batchculture of astaxanthin-rich Haematococcus pluvialis by exponential nutrient feeding and stepwise light supplementation. Bioproc.Biosys.Eng. 33,133–139,2010.
  18. Kang CD, Sim SJ Selective extraction of free astaxanthin from Haematococcus culture using a tandem organic solvent system.Biotechnol Prog. Jul-Aug; 23(4):866-71,2007.
  19. Karlawisha, J.; Jack, C.R.; Rocca, W.A.; Snyder, H.M.; Carillo, M.C. Alzheimer’s disease: The next frontier—Special report 2017. Alzheimers Dement., 13, 374–380, 2017.
  20. Kim, J.H.; Choi,W.; Lee, J.H.; Jeon, S.J.; Choi, Y.H.; Kim, B.W.; Chang, H.I.; Nam, S.W. Astaxanthin inhibits H2O2-mediated apoptotic cell death in mouse neural progenitor cells via modulation of P38 and MEK signaling pathways. J. Microbiol. Biotechnol., 19, 1355–1363,2009.
  21. Kim, Y.H.; Koh, H.K.; Kim, D.S. Down-regulation of IL-6 production by astaxanthin via ERK-, MSK-, and NF-?B-mediated signals in activated microglia. Int. Immunopharmacol, 10, 1560–1572, 2010.
  22. Liu, X.; Shibata, T.; Hisaka, S.; Osawa, T. Astaxanthin inhibits reactive oxygen species-mediated cellular toxicity in dopaminergic SH-SY5Y cells via mitochondria-targeted protective mechanism. Brain Res,1254, 18–27,2008.
  23. Liu, Z.; Zhou, T.; Ziegler, A.C.; Dimitrion, P.; Zuo, L. Oxidative stress in neurodegenerative diseases: From molecular mechanisms to clinical applications. Oxid. Med. Cell. Longev. 2017.
  24. Matsushita Y et al., Antioxidant activity of polar carotenoids including astaxanthin-b-glucoside from marine bacterium on PC liposomes, Fish Sci 66:980–985, 2000.
  25. Mercke Odeberg, J. Lignell, A. Pettersson, A. Höglund, P. Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. Eur. J. Pharm. Sci. 19, 299–304, 2003.
  26. Nunomura, A. Perry, G. Aliev, G. Hirai, K. Takeda, A. Balraj, E.K. Jones, P.K. Ghanbari, H. Wataya, T. Shimohama, S. et al. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol.60, 759–767, 2003.
  27. Ohgami, K.; Shiratori, K.; Kotake, S.; Nishida, T.; Mizuki, N.; Yazawa, K.; Ohno, S. Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Investig. Ophthalmol. Vis. Sci.,44,2694–2701, 2003.
  28. Ohno, S. Suppressive effects of astaxanthin against rat endotoxin-induced uveitis by inhibiting the NF-?B signaling pathway. Exp. Eye Res. 82, 275–281, 2006.
  29. Olson, J.A. Carotenoids: absorption, transport, and metabolism of carotenoids in humans. Pure Appl. Chem., 66, 1011–1016, 2004.
  30. Palozza, P and Krinsky, N I: Astaxanthin and canthaxanthin are potent antioxidants in a membrane model. Arch. Biochem. Biophys 297:291-295, 1992.
  31. Parker R.S., Absorption, metabolism, and transport of carotenoids. FASEB J. 10, 542–551, 1996.
  32. Peng J, Xiang W Z, Tang Q M., Sun N et al. Comparative analysis of astaxanthin and its esters in the mutant E1 of Haematococcus pluvialis and other green algae by HPLC with a C30 column. Sci China Ser. C-Life Sci 51:1108–1115, 2008.
  33. Configuration of astaxanthin, Pubchem website, available:https://pubchem.ncbi.nlm.nih.gov/compound/Astaxanthin.
  34. Puertas, M.C.; Martinez-Martos, J.M.; Cobo, M.P.; Carrera, M.P.; Mayas, M.D.; Ramirez-Exposito, M.J. Plasmaoxidative stress parameters in men and women with early stage Alzheimer type dementia. Exp. Gerontol, 47, 625–630,2012.
  35. Ranga Rao A, Raghunath Reddy, R L Baskaran, V Sarada R., Ravishankar G A: Characterization of microalgal carotenoids by mass spectrometry and their bioavailability and antioxidant properties elucidated in rat model. J. Agric. Food Chem. 58:8553–8559, 2010.
  36. Res, P.T.; Cermak, N.M.; Stinkens, R.; Tollakson, T.J.; Haenen, G.R.; Bast, A.; Van Loon, L.J. Astaxanthin supplementation does not augment fat use or improve endurance performance. Med. Sci. Sports Exerc. 45, 1158–1165, 82, 2013.
  37. Satoh, A.; Tsuji, S. Okada, Y. Murakami, N. Urami, M. Nakagawa, K.; Ishikura, M.; Katagiri, M.; Koga, Y.Shirasawa, T. Preliminary clinical evaluation of toxicity and efficacy of a new astaxanthin-rich Haematococcus pluvialis extract. J. Clin. Biochem. Nutr.,44, 280–284,2009.
  38. Shahidi, F, and Synowiecki, J: Isolation and Characterization of nutrients and value-added products from snow crab (Chinoecetes opilio) and shrimp (Pandalus borealis) processing discards. J. Agric. Food Chem 39: 1527–1532, 1991.
  39. Solomonov, Y.; Hadad, N.; Levy, R. The combined anti-inflammatory effect of astaxanthin, Lyc-O-Mato and Carnosic acid in vitro and in vivo in a mouse model of peritonitis. J. Nutr. Food Sci. 2008.
  40. Spiller, G.A.; Dewell, A. Safety of an astaxanthin-rich Haematococcus pluvialis algal extract: A randomized clinical trial. J. Med. Food, 51–56, 2003.
  41. (2019) Markets and markets website available: https://www.marketsandmarkets.com.
  42. Comparison of nutrients, Astareal Inc. Website,Revised from Nishida Y et al., 2007, sci.11:16-20.
  43. ALS image,Universiteitleiden website available :https://www.universiteitleiden.nl.
  44. Alzeimer’s disease image,Mount Sinai website: https://www.mountsinai.org.
  45. Parkinson’s disease image-Mayo clinic website available: https://newsnetwork.mayoclinic.org.
  46. Suzuki, Y.; Ohgami, K.; Shiratori, K.; Jin, X.H.; Ilieva, I.; Koyama, Y.; Yazawa, K.; Yoshida, K.; Kase, S.; Suppressive effects of astaxanthin against rat endotoxin-induced uveitis by inhibiting the NF-_B signaling pathway. Exp. Eye Res., 82, 275–281,2006.
  47. Tysnes, O.B.; Storstein, A. Epidemiology of Parkinson’s disease. J. Neural. Transm., 124, 901–905,2017.
  48. Urrutia, P.J.; Mena, N.P.; Núñez, M.T. The interplay between iron accumulation, mitochondrial dysfunction,and inflammation during the execution step of neurodegenerative disorders. Front. Pharmacol, 5, 38, 2014.
  49. Wildsmith, K.R.; Holley, M.; Savage, J.C.; Skerrett, R.; Landreth, G.E. Evidence for impaired amyloid clearance in Alzheimer’s disease. Alzheimers Res. Ther., 5, 33,2003.
  50. Ye, Q.; Huang, B.; Zhang, X.; Zhu, Y.; Chen, X. Astaxanthin protects against MPP+-induced oxidative stress in PC12 cells via the HO-1/NOX2 axis. BMC Neurosci., 13, 156,2012.
  51. Yook, J.S.; Okamoto, M.; Rakwal, R.; Shibato, J.; Lee, M.C.; Matsui, T.; Chang, H.; Cho, J.Y.; Soya, H. Astaxanthin supplementation enhances adult hippocampal neurogenesis and spatial memory in mice.Mol. Nutr. Food Res., 60, 589–599,2016.
  52. Zarei, S.; Carr, K.; Reiley, L.; Diaz, K.; Guerra, O.; Altamirano, P.F.; Pagani, W.; Lodin, D.; Orozco, G.; Chinea, A. A comprehensive review of amyotrophic lateral sclerosis. Surg. Neurol. Int., 6, 171, 2015.